When calculating EPS anticipates for the current year from sell-side analysts, the Price to current year EPS stands at -133.00%.
Advertisement
When it comes to the Analysis of a Stock, Price Target plays a vital role. Koffler has a 16.1% average return when recommending VRX, and is ranked #16 out of 4110 analysts. Mgt cited 2H tailwinds from seasonality (e.g., derm), expectations of improved performance in United States dermatology and GI following recent initiatives, front loaded R&D spend, and improved cost efficiencies as key reasons. Analyst’s mean target price for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is 42.61 while analysts mean recommendation is 3.00. Shares of company began trading at $63.12.
Valeant Pharmaceuticals has 343,030,000 shares now held by shareholders which now trade around the 25.09 mark which totals Valeant Pharmaceuticals’s market capitalisation to 8.61B Dollars.
The 52-week high of the share price is -0.75% and 52-week low of the share price is 73.14%.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s price to sales ratio for trailing twelve months is 0.91 and price to book ratio for most recent quarter is 1.72, whereas price to cash per share for the most recent quarter is 7.41.
Valeant had a $1.35 billion revolving line of credit, a $1.424 billion A-3 tranche A term loan, an $835.6 million A-4 tranche A term loan, a $1.053 billion D-2 tranche B term loan, an $808.9 million C-2 tranche B term loan, a $2.45 billion E-1 tranche B term loan and a $3.88 billion F tranche B term loan as of June 30, according to an earnings release. Valeant said it still sees full-year 2016 adjusted earnings of $6.60 to $7.00 a share, versus a $6.53 a share estimate, on revenue of $9.9 billion to $10.1 billion.
USA worker productivity fell for the third straight quarter in the spring this year, suggesting that corporate profits may continue to decline and wage growth may remain sluggish.
VRX has been the topic of a number of other research reports.
Piper Jaffray reiterated Neutral rating but has raised price target to $22 from $19. Mizuho reissued an “underperform” rating on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Finally, TheStreet cut shares of Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research report on Friday, April 15th. The stock has a consensus rating of “Hold” and a consensus target price of $59.66. Its weekly performance is 33.02% while year to date (YTD) performance is -72.30%. Current stock price is in the upbeat territory taking into account of 20 days moving average with 2.24% and continued bullish run for 50 days moving average with 6.58%. Shell Asset Management Co. now owns 43,020 shares of the specialty pharmaceutical company’s stock valued at $1,121,000 after buying an additional 938 shares during the period. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Other institutional investors have recently modified their holdings of the company.
Shares of specialty healthcare company Endo International Plc surged 21.8% on more than five times the average daily volume after the company delivered second-quarter results that topped analysts’ expectations. Breton Hill Capital Ltd. now owns 17,379 shares of the specialty pharmaceutical company’s stock valued at $350,000 after buying an additional 627 shares in the last quarter. Valeant Pharmaceuticals International (VRX) gained $5.16 at $27.61, a gain of 22.98% over the previous days close. Seven Bridges Advisors LLC boosted its stake in shares of Valeant Pharmaceuticals International by 2.2% in the second quarter.
Advertisement
Without ever trading a single share of stock, without buying an option and Without ever touching a mutual friend.
